CHOP’s recently published article entitled “Paradoxical activation and RAF inhibitor of BRAF protein kinase fusions characterizing pediatric astrocytomas”, in PNAS, April 9th, 2013, confirms that data supported the development of targeted treatment paradigms for BRAF-altered pediatric actrocytomas and also demonstrated that therapies might be tailored to the specific mutational context and distinct mechanisms of action of the mutant kinase. Read more.